|
BRPI0608907A2
(pt)
|
2005-05-10 |
2010-02-17 |
Itermune Inc |
método de modulação de sistema de proteìna cinase ativada por estresse
|
|
UA98297C2
(en)
*
|
2005-12-21 |
2012-05-10 |
Янссен Фармацевтика, Н.В. |
Triazolopyridazines as tyrosine kinase modulators
|
|
JP2009538899A
(ja)
*
|
2006-05-30 |
2009-11-12 |
ファイザー・プロダクツ・インク |
トリアゾロピリダジン誘導体
|
|
JP5415942B2
(ja)
|
2006-06-22 |
2014-02-12 |
プラナ バイオテクノロジー リミティッド |
処置の方法およびその処置に有用な薬剤
|
|
PE20121506A1
(es)
*
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
|
US8198448B2
(en)
|
2006-07-14 |
2012-06-12 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
|
US20080045514A1
(en)
*
|
2006-07-18 |
2008-02-21 |
Cytovia, Inc. |
3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof
|
|
WO2008021781A1
(en)
|
2006-08-07 |
2008-02-21 |
Incyte Corporation |
Triazolotriazines as kinase inhibitors
|
|
US8481538B2
(en)
|
2006-09-18 |
2013-07-09 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic inhibitors of c-Met and uses thereof
|
|
CA2669991C
(en)
|
2006-11-22 |
2016-01-26 |
Incyte Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
|
DK2137162T3
(en)
|
2007-03-15 |
2018-11-26 |
Novartis Ag |
Organic compounds and their applications
|
|
CN101678014B
(zh)
*
|
2007-05-21 |
2012-12-12 |
Sgx药品公司 |
杂环激酶调节剂
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
US8188083B2
(en)
|
2007-06-28 |
2012-05-29 |
Abbott Laboratories |
Triazolopyridazines
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
FR2919870B1
(fr)
*
|
2007-08-09 |
2014-05-16 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet
|
|
FR2929613B1
(fr)
*
|
2008-04-02 |
2010-12-31 |
Sanofi Aventis |
Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met
|
|
PA8792501A1
(es)
*
|
2007-08-09 |
2009-04-23 |
Sanofi Aventis |
Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
|
|
CN101878219B
(zh)
|
2007-09-27 |
2014-04-02 |
西班牙国家癌症研究中心 |
用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
KR20100128305A
(ko)
|
2008-02-28 |
2010-12-07 |
노파르티스 아게 |
Ｃ-ｍｅｔ 티로신 키나제 매개 질환의 치료를 위한 이미다조[1,2-ｂ]피리다진 유도체
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
CA2724742C
(en)
*
|
2008-05-21 |
2016-07-19 |
Incyte Corporation |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
|
EP2296653B1
(en)
|
2008-06-03 |
2016-01-27 |
Intermune, Inc. |
Compounds and methods for treating inflammatory and fibrotic disorders
|
|
DE102008028905A1
(de)
*
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
|
UY32049A
(es)
|
2008-08-14 |
2010-03-26 |
Takeda Pharmaceutical |
Inhibidores de cmet
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038220A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Oxadiazolderivate
|
|
DE102008038222A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
Indazol-5-carbonsäurehydrazid-derivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
JP5596047B2
(ja)
*
|
2008-11-19 |
2014-09-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ｃ−Ｍｅｔタンパク質キナーゼのトリアゾロチアジアゾール阻害剤
|
|
EP2356116A1
(en)
|
2008-11-20 |
2011-08-17 |
OSI Pharmaceuticals, Inc. |
Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
MY160526A
(en)
|
2008-12-22 |
2017-03-15 |
Merck Patent Gmbh |
Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
FR2941949B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941951B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941950B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
FR2941952B1
(fr)
*
|
2009-02-06 |
2011-04-01 |
Sanofi Aventis |
Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
|
|
SG172986A1
(en)
*
|
2009-02-10 |
2011-08-29 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
EP2406264A4
(en)
|
2009-03-09 |
2012-08-08 |
Univ California |
SUBSTITUTED HETEROCYCLES AND THEIR USE AS ALLOSTERIC MODULATORS OF NICOTINE AND GABAA RECEPTORS
|
|
HUE027964T2
(en)
|
2009-04-02 |
2016-11-28 |
Fund Centro Nac De Investig Oncologicas Carlos Iii |
Imidazo [2,1-b] [1,3,4] thiadiazole derivatives
|
|
CA2762186A1
(en)
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Substituted pyrazole inhibitors of c-met protein kinase
|
|
SI2435443T1
(sl)
*
|
2009-05-28 |
2013-12-31 |
Vertex Pharmaceuticals Incorporated |
Aminopirazol triazolotiadiazolni inhibitorji c-met protein kinaze
|
|
WO2010138673A1
(en)
*
|
2009-05-28 |
2010-12-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of c-met protein kinase
|
|
UA108618C2
(uk)
*
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
KR20120089463A
(ko)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
헤테로시클릭 옥심 화합물
|
|
BR112012016129B1
(pt)
*
|
2009-12-31 |
2020-11-03 |
Hutchison Medipharma Limited |
composto, composição e uso dos ditos compostos
|
|
ES2608329T3
(es)
|
2010-02-03 |
2017-04-07 |
Incyte Holdings Corporation |
Imidazo[1,2-b][1,2,4]triazinas como inhibidores de c-Met
|
|
AR081039A1
(es)
|
2010-05-14 |
2012-05-30 |
Osi Pharmaceuticals Llc |
Inhibidores biciclicos fusionados de quinasa
|
|
EP2569315A1
(en)
|
2010-05-14 |
2013-03-20 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
JP5960688B2
(ja)
|
2010-05-17 |
2016-08-02 |
インコゼン セラピューティクス プライベート リミテッド |
プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
|
|
EP2576568A1
(en)
|
2010-05-27 |
2013-04-10 |
Vertex Pharmaceuticals Incorporated |
An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
|
|
WO2012003338A1
(en)
|
2010-07-01 |
2012-01-05 |
Takeda Pharmaceutical Company Limited |
COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
|
|
AR085183A1
(es)
*
|
2010-07-30 |
2013-09-18 |
Lilly Co Eli |
Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer
|
|
EP2710003A1
(en)
|
2011-05-16 |
2014-03-26 |
OSI Pharmaceuticals, LLC |
Fused bicyclic kinase inhibitors
|
|
BR112014011254A2
(pt)
|
2011-11-11 |
2017-05-16 |
Pfizer |
2-tiopirimidinonas
|
|
EP2822931B1
(en)
|
2012-03-09 |
2017-05-03 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
US8916555B2
(en)
|
2012-03-16 |
2014-12-23 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
BR112014024251A8
(pt)
|
2012-03-30 |
2018-01-23 |
Rhizen Pharmaceuticals S A |
novos compostos piridina 3,5-dissubstituída-3h-imidazo [4,5-b] e piridina 3,5-dissubstituída -3h-[1,2,3]triazolo[4,5-b] como moduladores de quinases de proteína c-met
|
|
AR092742A1
(es)
|
2012-10-02 |
2015-04-29 |
Intermune Inc |
Piridinonas antifibroticas
|
|
JP6404230B2
(ja)
|
2012-12-20 |
2018-10-10 |
インセプション ２、 インコーポレイテッド |
トリアゾロン化合物およびその使用
|
|
CA2921420A1
(en)
|
2013-09-06 |
2015-03-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
MX368311B
(es)
|
2013-09-30 |
2019-09-27 |
Korea Res Inst Chemical Tech |
Nuevos derivados de triazolopirazina y usos de los mismos.
|
|
GB201321745D0
(en)
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
|
RU2692485C2
(ru)
|
2014-04-02 |
2019-06-25 |
Интермьюн, Инк. |
Противофиброзные пиридиноны
|
|
EP3229836B1
(en)
|
2014-12-09 |
2019-11-13 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Human monoclonal antibodies against axl
|
|
JP6450010B2
(ja)
|
2014-12-23 |
2019-01-09 |
アクシキン ファーマシューティカルズ インコーポレーテッド |
３，５−ジアミノピラゾールキナーゼ阻害剤
|
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
|
US10363254B2
(en)
|
2015-03-31 |
2019-07-30 |
University Of Vermont And State Agricultural College |
Methods for treating cryptosporidiosis using triazolopyridazines
|
|
CR20170498A
(es)
|
2015-05-05 |
2018-01-26 |
Pfizer |
2-tiopirimidinonas
|
|
PH12017502322B1
(en)
|
2015-06-25 |
2023-08-30 |
Taiho Pharmaceutical Co Ltd |
Therapeutic agent for fibrosis
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
RS62639B1
(sr)
|
2015-07-06 |
2021-12-31 |
Alkermes Inc |
Hetero-halo inhibitori histonskih deacetilaza
|
|
CA3001974A1
(en)
|
2015-10-14 |
2017-04-20 |
Bristol-Myers Squibb Company |
2,4-dihydroxy-nicotinamides as apj agonists
|
|
WO2017096130A1
(en)
|
2015-12-04 |
2017-06-08 |
Bristol-Myers Squibb Company |
Apelin receptor agonists and methods of use
|
|
TW201725203A
(zh)
|
2015-12-16 |
2017-07-16 |
必治妥美雅史谷比公司 |
作為ａｐｊ受體促效劑之雜芳基羥基嘧啶酮
|
|
MA43761A
(fr)
|
2016-03-24 |
2021-05-05 |
Bristol Myers Squibb Co |
6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides comme inhibiteurs de la apj
|
|
GR1009565B
(el)
*
|
2016-07-14 |
2019-08-06 |
Galenica Α.Ε. |
Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων
|
|
JP6756925B2
(ja)
|
2017-01-11 |
2020-09-16 |
ロダン・セラピューティクス，インコーポレーテッド |
ヒストンデアセチラーゼの二環式阻害剤
|
|
KR102323255B1
(ko)
|
2017-02-15 |
2021-11-08 |
다이호야쿠힌고교 가부시키가이샤 |
의약 조성물
|
|
JP6915907B2
(ja)
*
|
2017-05-26 |
2021-08-04 |
江▲蘇▼新元素医▲薬▼科技有限公司Ｊｉａｎｇｓｕ Ａｔｏｍ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． |
尿酸排泄を促進するｕｒａｔ１阻害剤
|
|
KR102680160B1
(ko)
*
|
2017-07-12 |
2024-06-28 |
브리스톨-마이어스 스큅 컴퍼니 |
심부전의 치료를 위한 rock의 5원-아미노헤테로사이클 및 5,6- 또는 6,6-원 비시클릭 아미노헤테로시클릭 억제제
|
|
ES2914355T3
(es)
|
2017-08-07 |
2022-06-09 |
Alkermes Inc |
Inhibidores bicíclicos de la histona desacetilasa
|
|
AU2018329881B2
(en)
|
2017-09-08 |
2021-12-02 |
Taiho Pharmaceutical Co., Ltd. |
Antitumor agent and antitumor effect potentiator
|
|
WO2019178129A1
(en)
|
2018-03-13 |
2019-09-19 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
WO2021055589A1
(en)
|
2019-09-18 |
2021-03-25 |
Shire Human Genetic Therapies, Inc. |
Heteroaryl plasma kallikrein inhibitors
|
|
PT4031547T
(pt)
|
2019-09-18 |
2024-08-27 |
Takeda Pharmaceuticals Co |
Inibidores de calicreína plasmática e utilizações dos mesmos
|
|
TR202009388A1
(tr)
*
|
2020-06-17 |
2021-12-21 |
Anadolu Ueniversitesi |
Akci̇ğer kanseri̇ tedavi̇si̇nde hedefe yöneli̇k yeni̇ tri̇azoloti̇yadi̇azi̇n türevleri̇
|
|
TR202010296A1
(tr)
|
2020-06-30 |
2022-01-21 |
Anadolu Ueniversitesi |
Akt inhibisyonu aracılığıyla a549 hücrelerinde sitotoksik ve apoptotik etki gösteren yeni triazol ve triazolotiyadiazin türevleri
|
|
AU2022215844A1
(en)
|
2021-02-02 |
2023-09-14 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
|
CN117355523A
(zh)
*
|
2021-03-17 |
2024-01-05 |
武田药品工业株式会社 |
血浆激肽释放酶的多环抑制剂
|